Boston Family Office’s Astria Therapeutics ATXS Stock Holding History

Boston Family Office’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-408	Closed	-$20K	–	248
2018 Q3	$20K	Hold	408	–	–	﹤0.01%	260
2018 Q2	$23K	Hold	408	–	–	﹤0.01%	259
2018 Q1	$44K	Hold	408	–	–	0.01%	256
2017 Q4	$36K	Hold	408	–	–	﹤0.01%	259
2017 Q3	$52K	Hold	408	–	–	0.01%	252
2017 Q2	$34K	Hold	408	–	–	﹤0.01%	250
2017 Q1	$39K	Buy	+408	New	+$56.2K	﹤0.01%	242

Other funds holding ATXS

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Boston Family Office's ATXS Position: Q4 2018 in Review

Boston Family Office sold out of Astria Therapeutics (ATXS) in Q4 2018, closing a stake of 408 shares — an estimated $20K sold.

Boston Family Office first reported a position in ATXS in Q1 2017 and held it in 7 quarters. The position peaked at $52K in Q3 2017. 23 funds tracked by Wall St. Rank hold ATXS as of Q4 2018.

Boston Family Office reported no remaining Astria Therapeutics position as of Q4 2018 after selling out during the quarter.
Boston Family Office sold 408 Astria Therapeutics shares in Q4 2018, an estimated $20K.
Boston Family Office first reported a position in Astria Therapeutics in Q1 2017 and held it in 7 quarters.
Boston Family Office's Astria Therapeutics position peaked at $52K in Q3 2017.
23 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2018.

Based on Boston Family Office's 13F filing for Q4 2018, filed 12 Feb 2019.